Abstract
The gastroprotective properties of tizanidine, a centrally acting myorelaxant, are discussed. It is noted that there is no strong evidence suggesting the ability of tizanidine to reduce the risk of serious gastrointestinal complications arising from with the use of nonsteroidal anti-inflammatory drugs and to decrease their need (average daily dose). It is stated that in inflammatory rheumatic diseases, myorelaxants (including tizanidine) are likely to be useful as a component of symptomatic therapy in a number of cases.
Highlights
The gastroprotective properties of tizanidine, a centrally acting myorelaxant, are discussed
It is noted that there is no strong evidence suggesting the ability of tizanidine to reduce the risk of serious gastrointestinal complications arising from with the use of nonsteroidal anti-inflammatory drugs and to decrease their need
It is stated that in inflammatory rheumatic diseases, myorelaxants are likely to be useful as a component of symptomatic therapy in a number of cases
Summary
The gastroprotective properties of tizanidine, a centrally acting myorelaxant, are discussed. Что тизанидин, как и другие миорелаксанты, – важный компонент комплексной терапии БНЧС. Серия хорошо организованных исследований показала, что комбинация тизанидина и НПВП более эффективна в отношении купирования острой БНЧС, чем монотерапия НПВП. При этом число осложнений со стороны желудочно-кишечного тракта (ЖКТ) было значительно выше в контрольной группе: 20 и 6% соответственно (р=0,02), хотя число больных, у которых возникли побочные эффекты со стороны ЦНС, было выше в группе комбинированной терапии: 33 и 9% соответственно (р=0,025).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
